Table 1

CFTR modulators licenced for use by the European Medicines Agency (EMA)

ModulatorYear of EMA licensingAge groupGenetics
Ivacaftor2012≥6 yearsHeterozygous G551D
2014≥6 yearsHeterozygous for additional gating mutations#
2015≥2 years
≥18 years
As above
Heterozygous R117H
2018≥12 monthsHeterozygous for gating mutations#
2019≥6 monthsAs above
2020≥4 monthsHeterozygous R117H
Heterozygous for gating mutations#
Lumacaftor/ivacaftor2015≥12 yearsHomozygous Phe508del
2017≥6 yearsAs above
2018≥2 yearsAs above
Tezacaftor/ivacaftor2018≥12 yearsHomozygous Phe508del or Phe508del+residual function mutation
2020≥6 yearsAs above
Elexacaftor/tezacaftor/ivacaftor2020≥12 yearsHomozygous Phe508del or Phe508del+minimal function mutation
2021≥12 yearsHeterozygous Phe508del

#: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1225P, S549N, S549R. : P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A>G, S945L, S977F, R1070W, D1152H, 2789+5G>A, 3272-26A>G, 3849+10kbC>T.